MA50651A - Récepteurs de lymphocytes t reconnaissant p53 mutée - Google Patents

Récepteurs de lymphocytes t reconnaissant p53 mutée

Info

Publication number
MA50651A
MA50651A MA050651A MA50651A MA50651A MA 50651 A MA50651 A MA 50651A MA 050651 A MA050651 A MA 050651A MA 50651 A MA50651 A MA 50651A MA 50651 A MA50651 A MA 50651A
Authority
MA
Morocco
Prior art keywords
mutated
lymphocyte receptors
lymphocyte
receptors
Prior art date
Application number
MA050651A
Other languages
English (en)
Inventor
Drew C Deniger
Winifred M Lo
Yong-Chen Lu
Parisa Malekzadeh
Maria R Parkhurst
Anna Pasetto
Paul F Robbins
Steven A Rosenberg
Rami Yoseph
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MA50651A publication Critical patent/MA50651A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA050651A 2017-09-29 2018-09-17 Récepteurs de lymphocytes t reconnaissant p53 mutée MA50651A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762565383P 2017-09-29 2017-09-29

Publications (1)

Publication Number Publication Date
MA50651A true MA50651A (fr) 2020-08-05

Family

ID=63714167

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050651A MA50651A (fr) 2017-09-29 2018-09-17 Récepteurs de lymphocytes t reconnaissant p53 mutée

Country Status (19)

Country Link
US (2) US11939365B2 (fr)
EP (2) EP3688027B1 (fr)
JP (3) JP7324193B2 (fr)
KR (2) KR102762272B1 (fr)
CN (2) CN111386282B (fr)
AU (2) AU2018342246B2 (fr)
BR (1) BR112020006012A2 (fr)
CA (1) CA3077024A1 (fr)
CR (4) CR20240302A (fr)
DK (1) DK3688027T3 (fr)
EA (1) EA202090757A1 (fr)
ES (1) ES3056082T3 (fr)
FI (1) FI3688027T3 (fr)
IL (1) IL273515B1 (fr)
MA (1) MA50651A (fr)
MX (4) MX421596B (fr)
PT (1) PT3688027T (fr)
SG (1) SG11202002636PA (fr)
WO (1) WO2019067243A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3551221T (pt) 2016-12-08 2022-01-18 Immatics Biotechnologies Gmbh Novos recetores de células t e imunoterapia empregando os mesmos
KR102809909B1 (ko) * 2017-09-29 2025-05-22 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법
KR20220013569A (ko) * 2019-05-27 2022-02-04 프로빈셜 헬스 서비시즈 오쏘리티 Kras 항원을 표적화하는 면역요법용 구조체
US12479902B2 (en) * 2019-06-27 2025-11-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing R175H or Y220C mutation in P53
CN113512124A (zh) * 2020-04-10 2021-10-19 香雪生命科学技术（广东）有限公司 一种识别hpv16的高亲和力tcr
US20230321240A1 (en) * 2020-09-04 2023-10-12 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services T cell receptors recognizing r273c or y220c mutations in p53
WO2022183167A1 (fr) 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Vecteurs recombinants comprenant des cassettes d'expression polycistronique et leurs procédés d'utilisation
AU2022268998A1 (en) * 2021-05-07 2023-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
WO2023050063A1 (fr) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 Tcr reconnaissant hla-a*02:01/e629-38, et son utilisation
CN118541388A (zh) * 2021-10-29 2024-08-23 侯亚非 识别p53中r175h突变的t细胞受体及其应用
WO2023150562A1 (fr) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Méthodes d'activation et d'expansion de lymphocytes t
US20240035027A1 (en) * 2022-05-04 2024-02-01 University Of Massachusetts Oligonucleotides for pms2 modulation
CN116063577B (zh) * 2022-11-18 2025-02-07 重庆医科大学 Tcr或其抗原结合片段及其应用
AU2024241888A1 (en) 2023-03-27 2025-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
AU2024298426A1 (en) * 2023-07-25 2026-01-15 Memorial Hospital For Cancer And Allied Diseases T cell receptors targeting tp53 hotspot mutations and uses thereof
WO2025060149A1 (fr) * 2023-09-22 2025-03-27 上海市第一人民医院 Tcr séparé et son utilisation
WO2025226769A1 (fr) * 2024-04-24 2025-10-30 Bluesphere Bio, Inc. Récepteurs des lymphocytes t ciblant l'antigène mineur d'histocompatibilité lhr-1
WO2025250587A1 (fr) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Expression de cytokine inductible pouvant être régulée par un médicament

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770749B2 (en) 2000-02-22 2004-08-03 City Of Hope P53-specific T cell receptor for adoptive immunotherapy
DK1546188T3 (da) * 2001-06-05 2008-10-27 Altor Bioscience Corp P53-bindende T-cellereceptormolekyler og anvendelser deraf
EP1545204B1 (fr) 2002-09-06 2016-08-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Immunotherapie utilisant des lymphocytes specifiques d'un antigene selectionnes in vitro apres une chimiotherapie non myeloablative appauvrissant les lymphocytes
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (fr) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédés de mise en croissance de lymphocytes infiltrant une tumeur dans contenants perméables au gaz
WO2015019318A1 (fr) * 2013-08-07 2015-02-12 Yeda Research And Development Co. Ltd. Peptides capables de réactiver des protéines p53 mutantes
CN106414748B (zh) * 2014-02-14 2021-05-28 得克萨斯州大学系统董事会 嵌合抗原受体及制备方法
CN106459924A (zh) * 2014-04-23 2017-02-22 得克萨斯州大学系统董事会 用于疗法中的嵌合抗原受体(car)及其制备方法
KR102618267B1 (ko) 2014-05-29 2023-12-27 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항-인유두종바이러스 16 e7 t 세포 수용체
JP6686008B2 (ja) * 2014-10-02 2020-04-22 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
CA2963364A1 (fr) 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methodes d'isolation de cellules t presentant une specificite antigenique pour une mutation specifique d'un cancer
CA2978628A1 (fr) 2015-03-03 2016-09-09 Caris Mpi, Inc. Profilage moleculaire du cancer
AU2016258845B2 (en) * 2015-05-01 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
US11047011B2 (en) * 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use

Also Published As

Publication number Publication date
US20240270814A1 (en) 2024-08-15
BR112020006012A2 (pt) 2020-10-06
EP4647442A3 (fr) 2026-03-04
JP2023159112A (ja) 2023-10-31
AU2024227695A1 (en) 2024-12-05
JP2025020145A (ja) 2025-02-12
KR20200064110A (ko) 2020-06-05
FI3688027T3 (fi) 2025-12-09
CN118955684A (zh) 2024-11-15
PT3688027T (pt) 2025-12-16
DK3688027T3 (da) 2025-12-15
CN111386282B (zh) 2024-09-06
US11939365B2 (en) 2024-03-26
MX2020003504A (es) 2020-09-14
AU2018342246A1 (en) 2020-04-16
MX2024005677A (es) 2024-06-11
CR20240302A (es) 2024-11-07
JP2021500010A (ja) 2021-01-07
EP4647442A2 (fr) 2025-11-12
EA202090757A1 (ru) 2020-08-21
JP7573075B2 (ja) 2024-10-24
MX2024005676A (es) 2024-06-11
SG11202002636PA (en) 2020-04-29
JP7814467B2 (ja) 2026-02-16
AU2018342246B2 (en) 2024-08-08
CA3077024A1 (fr) 2019-04-04
WO2019067243A1 (fr) 2019-04-04
ES3056082T3 (en) 2026-02-18
KR20250024096A (ko) 2025-02-18
US20200277352A1 (en) 2020-09-03
CR20200170A (es) 2020-11-23
CR20240303A (es) 2024-09-04
MX421596B (es) 2025-03-14
CR20250153A (es) 2025-06-03
IL273515B1 (en) 2025-11-01
IL273515A (en) 2020-05-31
MX2024005678A (es) 2024-06-11
EP3688027A1 (fr) 2020-08-05
KR102762272B1 (ko) 2025-02-07
EP3688027B1 (fr) 2025-09-10
CN111386282A (zh) 2020-07-07
JP7324193B2 (ja) 2023-08-09

Similar Documents

Publication Publication Date Title
MA50651A (fr) Récepteurs de lymphocytes t reconnaissant p53 mutée
MA47359A (fr) Récepteurs de lymphocytes t à appariement amélioré
FR23C1043I2 (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
IL271435A (en) T cell receptors
MA44608A (fr) Récepteurs des lymphocytes t
PT3494133T (pt) Recetores de células t anti-kras-g12d
PT3223850T (pt) Receptores de células t anti-kras mutado
IL260151A (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a 02 complex
IL262128A (en) T cell receptors
IL262124A (en) T cell receptors
IL262146A (en) T cell receptors
SG11202002425PA (en) Hla class ii-restricted t cell receptors against mutated ras
DK3448882T3 (da) Anti-kk-lc-1-t-cellereceptorer
EP3529611A4 (fr) Procédés de criblage de lymphocytes b
EP3383893A4 (fr) Récepteur de lymphocytes t à domaine variable unique
EP3286210C0 (fr) Récepteur de lymphocyte t
LT3433270T (lt) T ląstelių receptoriai
EP3724220A4 (fr) Récepteurs daric nkg2d
EP3578650A4 (fr) Nouveau récepteur des lymphocytes t
PL3661941T3 (pl) Pochodne tiazolopirydynowe jako antagoniści receptora adenozynowego
EP3527502A4 (fr) Récipient de séparation à stratification
MA46464A (fr) Polymorphes de l'agoniste de récepteur muscarinique
FI11640U1 (fi) Paloturvallinen keräyssäiliö
PT3676446T (pt) Dispositivo de separação
ES1139519Y (es) Bolsa de basura